BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Belimumab (Primary)
- Indications Membranous glomerulonephritis
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 08 Nov 2016 Status changed from active, no longer recruiting to completed.
- 04 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.